Toxins 2018, 10(1), 21; https://doi.org/10.3390/toxins10010021
Anti-Helicobacter pylori Properties of the Ant-Venom Peptide Bicarinalin
Jesus Guzman 1
, Nathan Téné 2, Axel Touchard 2, Denis Castillo 1, Haouaria Belkhelfa 3, Laila Haddioui-Hbabi 3, Michel Treilhou 2,†,*
and Michel Sauvain 1,4,†
, Nathan Téné 2, Axel Touchard 2, Denis Castillo 1, Haouaria Belkhelfa 3, Laila Haddioui-Hbabi 3, Michel Treilhou 2,†,*
and Michel Sauvain 1,4,†
1
Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia (UPCH), Lima 34, Peru
2
EA7417-BTSB, Université Fédérale Toulouse Midi-Pyrénées, INU Champollion, 81012 Albi, France
3
Fonderephar, Université de Toulouse, Faculté des Sciences Pharmaceutiques, 31062 Toulouse, France
4
UMR 152 PHARMADEV, Université de Toulouse, IRD, 31062 Toulouse, France
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 6 December 2017 / Revised: 22 December 2017 / Accepted: 23 December 2017 / Published: 29 December 2017
(This article belongs to the Special Issue Venom and Toxin as Targeted Therapy)
Abstract
The venom peptide bicarinalin, previously isolated from the ant Tetramorium bicarinatum, is an antimicrobial agent with a broad spectrum of activity. In this study, we investigate the potential of bicarinalin as a novel agent against Helicobacter pylori, which causes several gastric diseases. First, the effects of synthetic bicarinalin have been tested against Helicobacter pylori: one ATCC strain, and forty-four isolated from stomach ulcer biopsies of Peruvian patients. Then the cytoxicity of bicarinalin on human gastric cells and murine peritoneal macrophages was measured using XTT and MTT assays, respectively. Finally, the preventive effect of bicarinalin was evaluated by scanning electron microscopy using an adherence assay of H. pylori on human gastric cells treated with bicarinalin. This peptide has a potent antibacterial activity at the same magnitude as four antibiotics currently used in therapies against H. pylori. Bicarinalin also inhibited adherence of H. pylori to gastric cells with an IC50 of 0.12 μg·mL−1 and had low toxicity for human cells. Scanning electron microscopy confirmed that bicarinalin can significantly decrease the density of H. pylori on gastric cells. We conclude that Bicarinalin is a promising compound for the development of a novel and effective anti-H. pylori agent for both curative and preventive use. View Full-TextKeywords:
bicarinalin; antimicrobial peptide; Helicobacter pylori; gastric cells; bacterial adhesion; SEM
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Guzman, J.; Téné, N.; Touchard, A.; Castillo, D.; Belkhelfa, H.; Haddioui-Hbabi, L.; Treilhou, M.; Sauvain, M. Anti-Helicobacter pylori Properties of the Ant-Venom Peptide Bicarinalin. Toxins 2018, 10, 21.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.